Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...
Medically reviewed by Matthew Wosnitzer, MD Managing complement 3 glomerulopathy involves several treatment options aimed at ...